Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Buprenorphine 2mg sublingual tablets sugar free
0410030A0AAADAD
|
Buprenorphine (Opioid Dependance) | Buprenorphine hydrochloride | Central Nervous System | 15,126 |
|
Buprenorphine 8mg sublingual tablets sugar free
0410030A0AAAEAE
|
Buprenorphine (Opioid Dependance) | Buprenorphine hydrochloride | Central Nervous System | 14,583 |
|
Espranor 8mg oral lyophilisates
0410030A0BFABAM
|
Espranor | Buprenorphine hydrochloride | Central Nervous System | 11,350 |
|
Espranor 2mg oral lyophilisates
0410030A0BFAAAL
|
Espranor | Buprenorphine hydrochloride | Central Nervous System | 7,443 |
|
Subutex 8mg sublingual tablets
0410030A0BBACAE
|
Subutex | Buprenorphine hydrochloride | Central Nervous System | 3,262 |
|
Subutex 2mg sublingual tablets
0410030A0BBABAD
|
Subutex | Buprenorphine hydrochloride | Central Nervous System | 3,008 |
|
Buvidal 96mg/0.27ml prolonged-release inj pf syringes
0410030A0BGAFAT
|
Buvidal | Buprenorphine hydrochloride | Central Nervous System | 2,705 |
|
Buvidal 64mg/0.18ml prolonged-release inj pf syringes
0410030A0BGAEAS
|
Buvidal | Buprenorphine hydrochloride | Central Nervous System | 2,245 |
|
Buvidal 128mg/0.36ml prolonged-release inj pf syringes
0410030A0BGAGAU
|
Buvidal | Buprenorphine hydrochloride | Central Nervous System | 1,613 |
|
Subutex 0.4mg sublingual tablets
0410030A0BBAAAC
|
Subutex | Buprenorphine hydrochloride | Central Nervous System | 1,174 |
|
Buvidal 24mg/0.48ml prolonged-release inj pf syringes
0410030A0BGACAQ
|
Buvidal | Buprenorphine hydrochloride | Central Nervous System | 419 |
|
Buvidal 16mg/0.32ml prolonged-release inj pf syringes
0410030A0BGABAP
|
Buvidal | Buprenorphine hydrochloride | Central Nervous System | 368 |
|
Buvidal 8mg/0.16ml prolonged-release inj pf syringes
0410030A0BGAAAN
|
Buvidal | Buprenorphine hydrochloride | Central Nervous System | 235 |
|
Buprenorphine 2mg oral lyophilisates sugar free
0410030A0AAALAL
|
Buprenorphine (Opioid Dependance) | Buprenorphine hydrochloride | Central Nervous System | 215 |
|
Buvidal 160mg/0.45ml prolonged-release inj pf syringes
0410030A0BGAHAV
|
Buvidal | Buprenorphine hydrochloride | Central Nervous System | 208 |
|
Buvidal 32mg/0.64ml prolonged-release inj pf syringes
0410030A0BGADAR
|
Buvidal | Buprenorphine hydrochloride | Central Nervous System | 184 |
|
Buprenorphine 8mg oral lyophilisates sugar free
0410030A0AAAMAM
|
Buprenorphine (Opioid Dependance) | Buprenorphine hydrochloride | Central Nervous System | 126 |
|
Prefibin 2mg sublingual tablets
0410030A0BCABAD
|
Prefibin | Buprenorphine hydrochloride | Central Nervous System | 58 |
|
Buprenorphine 96mg/0.27ml prolonged-release inj pfs
0410030A0AAATAT
|
Buprenorphine (Opioid Dependance) | Buprenorphine hydrochloride | Central Nervous System | 57 |
|
Buprenorphine 128mg/0.36ml prolonged-release inj pfs
0410030A0AAAUAU
|
Buprenorphine (Opioid Dependance) | Buprenorphine hydrochloride | Central Nervous System | 55 |
|
Prefibin 8mg sublingual tablets
0410030A0BCACAE
|
Prefibin | Buprenorphine hydrochloride | Central Nervous System | 28 |
|
Prefibin 0.4mg sublingual tablets
0410030A0BCAAAC
|
Prefibin | Buprenorphine hydrochloride | Central Nervous System | 27 |
|
Buprenorphine 64mg/0.18ml prolonged-release inj pfs
0410030A0AAASAS
|
Buprenorphine (Opioid Dependance) | Buprenorphine hydrochloride | Central Nervous System | 22 |
|
Buprenorphine 160mg/0.45ml prolonged-release inj pfs
0410030A0AAAVAV
|
Buprenorphine (Opioid Dependance) | Buprenorphine hydrochloride | Central Nervous System | 20 |
|
Buprenorphine 24mg/0.48ml prolonged-release inj pfs
0410030A0AAAQAQ
|
Buprenorphine (Opioid Dependance) | Buprenorphine hydrochloride | Central Nervous System | 17 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.